Wikipedia

Lividomycin

Lividomycin is a broad-spectrum aminoglycoside antibiotic.[1] It is effective against most gram positive and gram negative bacteria including Mycobacterial tuberculosis (the causative agent of tuberculosis) and Pseudomonas aeruginosa.[2]

Lividomycin
Identifiers
  • (1R,2R,3S,4R,6S)-4,6-Diamino-3-hydroxy-2-{[α-D-mannopyranosyl-(1->4)-2,6-diamino-2,6-dideoxy-β-L-idopyranosyl-(1->3)-β-D-ribofuranosyl]oxy}cyclohexyl 2-amino-2,3-dideoxy-α-D-ribo-hexopyranoside
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H55N5O19
Molar mass777.775 g·mol−1
3D model (JSmol)
  • O([C@H]4[C@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@H]2O[C@@H](CN)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[C@H](O)[C@H]2N)[C@H]3O)[C@@H](O)[C@H](N)C[C@@H]4N)[C@H]5O[C@@H]([C@@H](O)C[C@H]5N)CO
  • InChI=1S/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29+/m1/s1
  • Key:DBLVDAUGBTYDFR-SWMBIRFSSA-N

References edit

  1. ^ Kobayashi F, Yamaguchi M, Mitsuhashi S (January 1972). "Activity of lividomycin against Pseudomonas aeruginosa: its inactivation by phosphorylation induced by resistant strains". Antimicrobial Agents and Chemotherapy. 1 (1): 17–21. doi:10.1128/AAC.1.1.17. PMC 444159. PMID 4207755.
  2. ^ Kobayashi F, Nagoya T, Yoshimura Y, Kaneko K, Ogata SI (February 1972). "Studies on New Antibiotic Lividomycins. V In vitro and in vivo antimicrobial activity of lividomycin A". The Journal of Antibiotics. 25 (2): 128–136. doi:10.7164/antibiotics.25.128. PMID 4624613.
 

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lividomycin&oldid=1184732059"